adagrasib,Pembrolizumab
mirati,merck
[]
 smi + pd1/pdl1 hepatotoxic is likely specific to the hepatotoxic metabolites of the smi. the immunotherapy enhances and reveals the hepatotoxic effects of the smi. so yes- specific to each individual smi. we've seen this across several different smis and classes of smis now.
Co-author of the cancer-immunity cycle and the immune set point with Ira Mellman; Opinions are my own.